Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial Post author:Sam Post published:November 7, 2017 Post category:BioPharma Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace You Might Also Like Why Celgene Should Consider Buying Rival Biogen January 23, 2017 MolecularMD Announces Partnership With To Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services September 28, 2017 This is the Fastest-Growing Private Pharma in the Bay Area October 29, 2017
MolecularMD Announces Partnership With To Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services September 28, 2017